|
|
More recently in early-stage clinical trials, the life sciences industry has observed an increase in Phase 1/2a trials being designed to draw inference about preliminary response rates. These design changes are, in part, due to the use of biomarkers and adaptive design approaches that enhance the early detection of efficacy signals.
|